The primary inflammatory site and plausible cause guide targeted tests; images show different aspects of activity and damage. Infection and masquerade disease require their own pathway.
Terminology and draft status
Terminology review is not complete. Selected actual WHO UMD queries and their limits are recorded in terminology.md; they do not approve the whole translation.
01Classify the primary site and activity
Uveitis may be infectious, immune-mediated, idiopathic after an appropriate assessment, or a masquerade such as malignancy. The primary site defines anterior disease in the anterior chamber, intermediate disease in the vitreous, posterior disease in retina/choroid and panuveitis across these compartments. Iritis, iridocyclitis/anterior cyclitis and retinitis/choroiditis/chorioretinitis/retinochoroiditis/neuroretinitis describe related anatomical patterns. 2
Pars planitis is not a synonym for every idiopathic intermediate uveitis: it requires vitreous inflammation with snowballs or snowbanks and no associated infection or systemic disease. Anterior spillover cells do not alone make the vitreous the primary site. Record snowballs, snowbanking and pars-plana vascularisation separately, and evaluate their cause. 2
Describe onset as sudden or insidious and duration as limited (up to 3 months) or persistent (more than 3 months). Acute means sudden onset with limited duration; recurrent episodes are separated by at least 3 months of inactivity without treatment. Chronic disease is persistent and relapses promptly, within 3 months after treatment stops. Duration alone is not the entire course classification. 2
SUN anterior cells are grade 0 below 1 cell, 0.5+ at 1–5, 1+ at 6–15, 2+ at 16–25, 3+ at 26–50 and 4+ above 50 cells in that field. Hypopyon is recorded separately, not automatically converted to cell grade 4+. Fibrin can obscure assessment and belongs in its own description; severe flare with fibrin is not the same scale as cell count. Vitreous haze is graded by disc and vessel visibility, separately from anterior cells. 2
Anterior disease is common, but the original 70–90% proportion depends on the clinical population and is not universal. Flare can persist with barrier damage after cells resolve. Inactivity and steroid-free control differ from treatment-free remission; a two-year steroid-free goal is a long-term aspiration, not SUN’s ≥3 months off all eye-disease treatment definition. 1 2
02Examine systematically and recognise patterns
Record age, symptoms and laterality, prior operations or trauma, medicines, autoimmune disease, travel/exposure and family history. Ask about skin/psoriasis, oral or genital ulcers, joints, lung, bowel and urinary symptoms. A structured questionnaire supports completeness. The original quoted psoriasis-family-history maxim is not a diagnostic rule: family history changes probability, not proof. 2
Anterior disease may cause redness, light sensitivity, pain, altered vision and tearing; the original RSPV mnemonic helps explain symptoms but is not a diagnostic rule. Children with JIA may have a white, asymptomatic eye. Intermediate/posterior disease often causes floaters, photopsias and visual loss, and may show vascular sheathing, retinal/choroidal lesions, macular or disc oedema, optic-nerve involvement, neovascularisation or tractional, rhegmatogenous or exudative detachment. 2
Before dilation where feasible, document iris nodules, atrophy, pupil and cells so pigment release does not confuse the count. Use a dark room, bright narrow beam, oblique illumination and high magnification; the original at least 16× and 1–2 mm width are technique descriptions, while SUN cell grading uses a 1×1 mm field. Cells descend near the cooler cornea and rise near the iris. Record the technique for serial comparison. 2
Fine KPs suggest non-granulomatous and large mutton-fat KPs granulomatous inflammation; white versus pigmented/grey deposits and diffuse versus Arlt-triangle distribution help describe timing and morphology but do not identify an organism alone. Stellate diffuse KPs and iris atrophy suggest Fuchs; sectoral atrophy and pressure elevation raise HSV/VZV/CMV questions. Koeppe nodules are at the pupil margin and Busacca nodules on the iris stroma. 2
A cold or shifting hypopyon can occur in Behçet disease but is not specific and does not exclude infection, malignancy or synechiae. An inverse pseudohypopyon may be floating silicone oil. Record blood, fibrin and anterior/posterior synechiae; one-sided disease suggests infection or HLA-B27 among other causes, while pressure rise can accompany herpes, Fuchs or Posner–Schlossman. Keratouveitis and sclerouveitis broaden the differential to infection and systemic vasculitis such as GPA/PAN. 2
Band keratopathy may accompany chronic JIA uveitis, sarcoidosis or other calcium/inflammation disorders. Extensive synechiae can occur in JIA, sarcoidosis and spondyloarthritis. Cotton-wool lesions are non-specific and can accompany SLE, HIV or other retinal disease; they do not alone establish CMV retinitis. Large granulomas raise sarcoid/TB questions. A quiet white eye does not exclude childhood inflammation. 2
HLA-B27 may cause alternating acute anterior episodes; JIA may be silent, TINU may include renal disease, sarcoid may involve multiple segments and Behçet may cause occlusive retinal vasculitis. The hypertensive mild-cell Posner–Schlossman phenotype raises CMV questions; the original table’s generic rubella attribution must not be treated as equivalent to the distinct rubella-associated Fuchs context. No pattern alone proves the organism. 1 3
| Disease | Clinical pattern and limits |
|---|---|
| HLA-B27 | Acute alternating anterior disease; fibrin/hypopyon possible |
| HSV/VZV/CMV | Unilateral pressure rise, corneal/iris clues; phenotype alone not virus proof |
| Fuchs | Mild chronic disease, stellate KPs, atrophy; heterochromia optional |
| Posner–Schlossman | Marked pressure with mild cells; CMV important but not every case confirmed |
| JIA | Often silent bilateral anterior disease in children; screening essential |
| Behçet | Possible panuveitis and occlusive vasculitis; hypopyon not specific |
| Sarcoidosis | Often granulomatous multiple-segment disease; systemic assessment |
| TINU | Often bilateral anterior disease plus renal findings; not only young women |
03Ask what each image can show
Photography documents location and change. Wide-field imaging can show peripheral disease but is not automatically superior for every purpose or a replacement for examination. FAF reflects fluorophores and optical blockage as well as RPE status: bright regions can persist in inactive MFCPU/PIC, and dark areas can reflect atrophy or blockage. FAF brightness alone does not classify all white-dot, serpiginous, birdshot or VKH activity. 4
FA demonstrates retinal vascular leakage, disc leakage, petaloid macular oedema and non-perfusion; fern-like leakage can accompany Behçet and multiple pinpoint leaks VKH. Findings are not disease-specific. ICGA adds choroidal information in selected birdshot, VKH, serpiginous or TB questions; late dark lesions do not automatically mean active inflammation, and a dark disc is an imaging characteristic rather than a diagnostic endpoint. 4
OCT quantifies macular fluid and structural change; ellipsoid-zone integrity can relate to vision but is not a universally strongest prognostic marker across all uveitis. EDI-OCT helps assess choroidal thickness. OCTA shows flow signals and may help assess non-perfusion or inflammatory CNV, but cannot show leakage and is vulnerable to segmentation/slow-flow artefacts. 4
B-scan is valuable when cataract, haemorrhage or inflammation obscures the fundus and can identify detachment, vitreous opacity or posterior scleral changes. A T-sign supports posterior scleritis, but its absence does not exclude it. Ultrasound and UBM results depend on technique and anatomy; they do not replace a cause-specific assessment or provide universal diagnostic cutoffs. 4
04Select laboratory and ocular-fluid tests
Hypothesis-driven tests reduce misleading incidental results, but laboratory or tissue evidence can be essential, not merely optional confirmation. Select syphilis treponemal/non-treponemal testing, TB skin/IGRA and chest assessment, or sarcoid ACE/lysozyme/chest imaging according to phenotype and risk; biopsy can establish systemic sarcoidosis when appropriate. Positive toxoplasma IgG or herpes serology alone does not diagnose ocular infection, and negative herpes serology is not a universal exclusion. 2
Selected aqueous or vitreous sampling can test suspected viruses, toxoplasma or TB, or investigate malignancy; PCR sensitivity, timing, prior treatment and sample handling matter. Clinical diagnoses such as VKH or sympathetic ophthalmia still require exclusion of plausible alternatives. Coordinate systemic investigations and urgent treatment rather than ordering every test indiscriminately. 2
Bilateral, recurrent, granulomatous, intermediate/posterior disease, poor treatment response or systemic symptoms often justify broader directed assessment. A first typical unilateral anterior episode may need fewer tests; that is not a prohibition on testing when risk suggests infection or systemic disease. Pair treponemal and non-treponemal syphilis tests and choose chest assessment according to sarcoid/TB suspicion. 1
Read the TB skin test at48–72 hours, measuring induration rather than redness. CDC thresholds are ≥5 mm for specified highest-risk groups, ≥10 mm for other defined risk groups and ≥15 mm without known risk factors: the original strict >5/>15 shortcut omits a category and the equality boundaries. BCG can affect skin tests; IGRA is not affected by BCG. Neither test alone proves active or ocular TB, and local guidance remains necessary. 6
05Escalate treatment for the disease, not a rigid ladder
Control non-infectious inflammation while minimising steroid harm. Topical prednisolone/dexamethasone treats anterior activity, including anterior involvement accompanying posterior disease, but does not alone treat significant posterior inflammation. Periocular/intravitreal triamcinolone or dexamethasone implant (Ozurdex) and systemic treatment have different indications and risks. Sight-threatening VKH, sympathetic ophthalmia, posterior Behçet or vasculitis may need early potent systemic therapy rather than sequentially failing every step. 5
The original oral prednisolone 1 mg/kg/day, maximum 60–80 mg, and chronic 7.5 mg/day threshold are contextual examples, not a dosing instruction for every age or disease. Dose, taper and prevention of infection/bone/metabolic harms need current labels and specialist plans. NSAIDs may have adjunct roles, including selected scleritis or pseudophakic oedema, but are not a mandatory evidence-based second rung for all uveitis. 1 5
Steroid-sparing options include weekly methotrexate, daily azathioprine or mycophenolate and selected ciclosporin with renal/BP monitoring. The original 6–8 week antimetabolite onset is approximate and cannot justify leaving active sight threat untreated. Drug-specific blood/liver/renal and reproductive counselling are essential; azathioprine can be considered in selected pregnancy contexts but is not universally the best choice, and mycophenolate requires strict pregnancy prevention. Cyclophosphamide/chlorambucil are reserved toxic options with infection, infertility and malignancy concerns. 5
Adalimumab (Humira), a human anti-TNF antibody, has specific non-infectious uveitis indications and regimens; the original every 2 weeks example is not a universal regimen for all ages or anatomical types. Infliximab (Remicade) is intravenous with different approval/off-label context. Screen for active and latent TB and manage prophylaxis when indicated rather than excluding all latent infection forever. Demyelination requires specialist assessment; do not infer a universal MRI mandate from a summary. 5
Interferon in selected refractory Behçet, rituximab targeting CD20 and IVIG are specialised options, not interchangeable routine steps after anti-TNF. IVIG is an immunoglobulin treatment rather than a cytokine-targeted biologic equivalent. Compare actual disease-specific evidence, safety and local approvals; uncontrolled response percentages across different populations cannot prove one agent superior. Continue activity, pressure, macular and systemic-toxicity monitoring while planning any taper. 5
| Disease | Clinical pattern | Imaging | Treatment boundary |
|---|---|---|---|
| HLA-B27 | Acute recurrent anterior disease | FA/OCT may be normal unless oedema/posterior disease | Topical treatment; selected systemic escalation |
| Herpetic | Unilateral pressure/corneal/iris pattern | Clinical plus selected PCR | Specific antiviral and supervised steroid care |
| Behçet | Panuveitis/occlusive vasculitis possible | FA leakage/ischaemia; ICGA for selected question | Prompt potent systemic care if posterior sight threat |
| Sarcoidosis | Granulomatous anterior or panuveitis | FA/OCT/FAF/ICGA answer different questions | Steroid and selected steroid-sparing treatment |
| VKH | Bilateral inflammation/serous detachment; skin/hair changes may follow | Pinpoint FA leakage, dark ICGA spots, OCT fluid | Early systemic therapy after differential review |
| Fuchs | Mild chronic anterior pattern | Imaging for complications, not necessarily normal | Avoid unnecessary chronic steroids; manage cataract/glaucoma |
What are the main learning points?
The primary inflammatory site and plausible cause guide targeted tests; images show different aspects of activity and damage. Infection and masquerade disease require their own pathway.
When is assessment urgent?
Rapid visual loss, severe pain, marked inflammation or pressure rise, hypopyon, suspected retinal infection or neurological disease needs urgent assessment.
References and access status
- 1Immutable original export; combined diagnosis/imaging/therapy lecture; own three original video identities
Complete export read; original attribution and any recording/transcript or appointment not independently verified.
- 2SUN2005 definitions and grading
Historical 080 table/definition access 10 November and selected indexed source 15 November; direct access challenged. No newly read full source.
- 3SUN CMV anterior uveitis criteria 2021
Selected indexed original introduction read 15 November 2026; phenotype does not reliably identify every CMV infection. Full methods/performance not appraised.
- 4Review 024: imaging source appraisal
Historical 6 November selected primary imaging/regulatory source access reused; no fresh full-paper/figure/label appraisal. Persistent hyper-FAF and ICGA limits retained.
- 5Review 023: steroid-sparing therapy and product/source limits
Historical 6 November selected EMA/FAST/VISUAL/FOCUS and pregnancy/infection evidence reused at its recorded scope; complete current labels/protocols still pending.
- 6CDC tuberculin skin test guidance
Selected indexed official interpretation section read 15 November 2026; ≥5/≥10/≥15 mm depend on risk. US test interpretation, not a diagnosis of ocular TB or a German treatment protocol.
- 7DOG/BVA24a intermediate uveitis 2020 / SUN pars planitis 2021
Selected indexed introduction/Table 3 and DOG definition read 15 November 2026, not complete performance study/guideline.
Original lecture link
For patients
Different types of eye inflammation need different tests. Medicines and follow-up are selected to control disease while limiting harm; do not change treatment from a summary table.
Examination and selected tests guide individual treatment and follow-up; this educational text cannot replace your own assessment.
Rapid visual loss, severe pain, marked inflammation or pressure rise, hypopyon, suspected retinal infection or neurological disease needs urgent assessment.
Rapid visual loss, severe pain, marked inflammation or pressure rise, hypopyon, suspected retinal infection or neurological disease needs urgent assessment.